Browse by Audience
Skip to content
Papers of the Week
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
Authors
Abstract
Calcitonin gene-related peptide-targeted drugs have proven safe and effective for migraine prevention in large randomized-controlled, double-blind trials with an average duration of six months. Open-label studies may provide additional information on the long-term safety and efficacy of these substances.